Drug Profile
Research programme: resistant hypertension therapeutics - PhytoPharmacon
Alternative Names: SP 002Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PhytoPharmacon LLC
- Developer PhytoPharmacon
- Class
- Mechanism of Action Endothelin receptor antagonists; Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Resistant hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Resistant-hypertension in USA
- 04 Jun 2008 Preclinical trials in Resistant hypertension in USA (unspecified route)